MRK Stock Analysis: Buy, Sell, or Hold?
MRK - Merck & Co., Inc.
$113.45
1.08 (0.96%)
▲
5d:
-0.1%
30d:
-5.43%
90d:
-4.91%
BUY
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.0/10
Get Alerted When MRK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called MRK this week
50% bullish • 2 bearish
50% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MRK shows positive signals but monitor for confirmation. Market pricing in 2.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: MRK shows positive signals but monitor for confirmation. Market pricing in 2.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$239.97
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$149.00
23.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MRK is currently trading at $113.45, which is considered fair relative to its 30-day fair value range of $110.94 to $119.21. The stock's valuation (Forward PE: 11.8) is in line with its historical norms (12.8). Remarkably, the market is currently pricing in an annual earnings decline of 2.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MRK is in a uptrend. The price is approaching resistance at $114.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $129.74 (+14.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MRK is in a uptrend. The price is approaching resistance at $114.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $129.74 (+14.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$110.94 -
$119.21
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($129.74)
Trading Range Analysis
30-Day Trading Range
$110.94 -
$119.21
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$108.63
Resistance Level
$114.62
Current Trend
Uptrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.78
Wall Street Target
$129.74
(+14.4%)
Revenue Growth (YoY)
4.9%
Earnings Growth (YoY)
-19.3%
Profit Margin
13.6%
Valuation Discount vs History
-2.8% cheaper
PE vs Historical
11.8 vs 12.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.8%
(market-implied from PE analysis)
1-Year Target
$110.27
(-3%)
2-Year Target
$107.19
(-6%)
3-Year Target
$104.18
(-8%)
3-Yr Target (if PE normalizes)
(PE: 12→13)
$113.17
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 216.7%)
$716.13
(+531%)
Base:
(SPY PE: 11.8, Growth: 216.7%)
$382.89
(+238%)
Bear:
(PE: 10.0, Growth: 216.7%)
$325.46
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 31.35 | Current EPS (TTM): $3.55
Bull Case
$244.82
(+116%)
Analyst growth 100.0%, PE expands to 34.5
Base Case
$222.56
(+96%)
Market implied 100.0%, PE stable at 31.4
Bear Case
$75.67
(-33%)
Severe decline -20.0%, PE contracts to 26.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.8 to 12.8
Stabilization Target:
$123.23
(+8.6%)
PE Expansion Potential:
+8.6%
Share & Embed Analysis
Last updated: May 14, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRK showing a specific setup today?
Insider Activity (6 Months)
4
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-10
Chirfi Guindo
SELL
10000 shares
2026-02-09
Jennifer Zachary
SELL
121573 shares
2026-02-09
Featured in Portfolios
MRK is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 59 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$252 | 63 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$217 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 58 HOLD |
Advanced MRK Option Strategies
Professional options setups generated by AI based on today's MRK price and gamma walls.
